EP1140099A1 - Verwendung von 2-substituierten 1,2-benzisothiazol-derivaten und von 3-substituierten tetrahydropyridopyrimidinon-derivaten zur prophylaxe und therapie der zerebralen ischämie - Google Patents

Verwendung von 2-substituierten 1,2-benzisothiazol-derivaten und von 3-substituierten tetrahydropyridopyrimidinon-derivaten zur prophylaxe und therapie der zerebralen ischämie

Info

Publication number
EP1140099A1
EP1140099A1 EP99966990A EP99966990A EP1140099A1 EP 1140099 A1 EP1140099 A1 EP 1140099A1 EP 99966990 A EP99966990 A EP 99966990A EP 99966990 A EP99966990 A EP 99966990A EP 1140099 A1 EP1140099 A1 EP 1140099A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
branched
unbranched
substituted
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99966990A
Other languages
German (de)
English (en)
French (fr)
Inventor
Gerd Steiner
Kurt Schellhaas
Wilfried Lubisch
Uta Holzenkamp
Dorothea Starck
Laszlo Szabo
Franz Emling
Francisco Javier Garcia-Ladona
Hans-Peter Hofmann
Liliane Unger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of EP1140099A1 publication Critical patent/EP1140099A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the invention relates to the use of compounds of formula I for the prophylaxis and therapy of cerebral ischemia
  • R 1 for hydrogen, (C ⁇ _ 6 ) Al yl branched or unbranched, CO- (C ⁇ _ 4 ) alkyl, C0 2 tBu, CO-aryl and a phenylalkyl- C 1 -C 4 -R.es, which in turn on the aromatic F, Cl, Br, I, 5 1 -C alkyl, C 1 -C 4 alkoxy, trifluoroethyl, hydroxy, amino, cyano or nitro may be substituted,
  • A is branched or unbranched (C ⁇ - ⁇ o) -alkylene or straight-chain or branched (C2 10) -alkylene which 0 comprises at least one group Z which is selected from 0, S, MR2, cyclopropyl, CHOH, a double or a triple bond,
  • R 2 represents hydrogen and C 1 -C 4 alkyl, 5
  • B stands for 4-piperidine, 4-tetrahydro-l, 2, 3, 6 pyridine, 4-piperazine and the corresponding ring compounds enlarged by a methylene group, the linkage to A taking place via an N atom of B and 0
  • Ar for phenyl which may be branched or unbranched by (C ⁇ _ 6 ) alkyl, O- (C ⁇ _ 6 ) alkyl branched or unbranched, OH, F, Cl, Br, I, trifluoromethyl, NR 2 2 , C0 2 R 2 , cyano or substituted phenyl, tetralin, indane, more highly condensed 5 aromatics such as naphthalene, which is optionally substituted by (C ⁇ ) alkyl or 0 (C ⁇ -) alkyl, anthracene or 5- or 6-membered aromatic heterocycles with 1 to 2 hetero - ato en, which are independently selected from O and N, which can be fused with other aromatic radicals.
  • A, X and Y have the meaning given above and Q represents a cleavable group (for example Cl, Br, I, alkanesulfonyloxy or arylsulfonyloxy), with a compound of the formula III,
  • B 1 is piperazine or homopiperazine and W is hydrogen or one of the usual amino protecting groups (such as Boc or Cbz), with a compound of general formula VIII
  • P is B (OH) 2 , SnR 3 , OTf, Br, Cl, or I and R is iC 4 -Al yl, in a known manner; or
  • B2 is 4-tetrahydro-l, 2, 3, 6-pyridine and the corresponding ring compounds enlarged by a methylene group and Pi is Cl, Br, I, SnR 3 - where R is C 1 -C 4 -alkyl, OTf with a compound of the general formula X
  • B 3 represents piperidines linked in the 1,4-position and the corresponding ring compounds enlarged by a methylene group
  • the hydrochloride was precipitated from the solution of the residue in ethyl acetate by adding 30% isopropanol / HCl solution, which was dried in a vacuum drying cabinet at 40 ° C. after suction. 17 g (67%) of substance were obtained. Mp ..- 200 ° C.
  • the aqueous phase was filtered, made alkaline and extracted with dichloromethane. After drying over sodium sulfate and extensive removal of the solvent, the mixture was diluted with diethyl ether and the hydrochloride was precipitated with ethereal hydrochloric acid. 3.2 g (67%) of the product were obtained. (Mp: 293 ° C).
  • R 1 , R 2 independently of one another represent (C ⁇ - ⁇ ) alkyl
  • R 3 , R 4 independently of one another for hydrogen, (C ⁇ _ 6 ) alkyl branched or unbranched, OH, 0- (C ⁇ - 6 ) alkyl branched or unbranched, F, Cl, Br, I, trifluoromethyl, NR 5 R 6 , C0 2 R 7 , nitro, cyano, pyrrole, for a phenylalkyl C 1 -C 4 radical, which in turn is aromatic on F, Cl, Br, I, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, trifluoromethyl , Hydroxy, amino, cyano or nitro can be substituted,
  • R 5 , R 6 independently of one another for hydrogen, (C ⁇ - 6 ) alkyl branched or unbranched, COPh, C0 2 tBu, CO- (C ⁇ _ 4 ) alkyl or together for a 5- or 6-membered ring which may optionally be a second N contains (e.g. piperazine),
  • R 7 represents hydrogen and (C ⁇ _g) alkyl branched or unbranched
  • A represents branched or unbranched (C ⁇ _ ⁇ o) alkylene or straight-chain or branched (C_ ⁇ o) alkylene which comprises at least one group Z which is selected from 0, S, NR 7 , cyclopropyl, CHOH, a double or a triple bond,
  • B represents 4-piperidine, 4-tetrahydro-l, 2, 3, 6 pyridine, 4-piperazine and the corresponding ring compounds enlarged by a methylene group, the linkage to A taking place via an N atom of B and
  • Ar for phenyl which is optionally branched or unbranched by (Ci- ⁇ ) alkyl, 0- (Ci- ⁇ ) alkyl branched or unbranched, OH, F, Cl, Br, I, trifluoromethyl, NR 5 R 6 , C0 2 R 7, cyano or phenyl, tetralin, indan, highly condensed aromatics such as naphthalene, which is optionally substituted by (C 1 - 4) alkyl or 0 (C ⁇ _ 4) is substituted alkyl, anthracene or 5- or 6-membered aromatic heterocycles having 1 up to 2 heteroatoms, which are independently selected from 0 and N, and those with others aromatic residues can be fused, for example quinoline, isoquinoline, phthalazine, indole and quinazoline, which in turn can be substituted with phenyl,
  • R 1 to R 4 and A have the meaning given above and Q represents a cleavable group (for example Cl, Br, I, alkanesulfonyloxy or arylsulfonyloxy), with a secondary amine of the formula III,
  • B 1 is piperazine or homopiperazine and W is hydrogen or one of the usual amino protecting groups (such as Boc or Cbz), with a compound of general formula VIII
  • P is B (OH) 2 , SnR 3 , OTf, Br, Cl, or I and R is C 1 -C 4 -alkyl, in a known manner; or
  • B 3 represents piperidines linked in the 1,4-position and the corresponding ring compounds enlarged by a methylene group;
  • Example 2 3, 3-Dimethyl-2- [3- (4- (2-phenylquinazoline-4-yl) piperazin-1-yl) prop-1-yl] -2, 3-dihydro-l, 2-benzisothiazole-1,1-dioxide (mp: 269 ° C., hydrochloride).
  • Example 3 3, 3-Dimethyl-2- [3- (4-quinolin-2-yl-piperazine-l-yl) prop-1-yl] -2, 3-dihydro-l, 2-benzisothiazole- l, 1-dioxide (mp: 63 ° C).
  • Example 4 3, 3-Dimethyl-2- [3- (4-naphth-l-yl-l, 4-diazapan-l-yl) prop-l-yl] -2, 3-dihydro-l, 2-benzisothiazole-l, 1-dioxide (mp: 126 ° C, hydrochloride).
  • Example 5 3,3-dimethyl-2- [3- (4- (4-chlorophthalazin-l-yl) piperazin-1-yl) eth-l-yl] -2, 3-dihydro-l, 2-benzisothiazole-l, l-dioxide (mp: 190 ° C.).
  • Example 6 3, 3-Dimethyl-2- [3- (4-naphth-l-yl-piperazine-l-yl) -2-methylene prop-l-yl] -2, 3-dihydro-1,2 -benzisothiazole-l, l-dioxide (mp: 193 ° C).
  • Example 7 3, 3-Dimethyl-2- [2- (4-quinazolin-4-yl-piperazine-1-yl) eth-1-yl] -2, 3-dihydro-1, 2-benzisothiazole- l, 1-dioxide (mp: 178 ° C, hydrochloride).
  • Example 8 3, 3-Dimethyl-2- [2- (4-naphth-l-yl-piperazine-l-yl) eth-l-yl] -2, 3-dihydro-l, 2-benzisothiazole- l, 1-dioxide (mp: 282 ° C, hydrochloride).
  • Example 9 3, 3-Dimethyl-2- [2- (4-isoquinolin-4-yl) piperazin-1-yl) eth-l-yl] -2, 3-dihydro-l, 2-benziso - thiazole-1,1-dioxide (mp: 243 ° C, hydrochloride).
  • Example 10 3,3-Diethyl-2- [2- (4-naphth-l-yl-piperazine-l-yl) eth-l-yl] -2, 3-dihydro-l, 2-benzisothiazole- l, 1-dioxide (oil).
  • Example 11 3,3-Dimethyl-2- [3- (4-naphth-l-yl-piperazine-l-yl) prop-1-yl] -6-pyrrole-l-yl-2,3- dihydro-l, 2-benzisothiazole-l, l-dioxide (mp: 269 ° C., hydrochloride).
  • the pyrrole ring was formed by reacting 3, 3-dimethyl-2- [3- (4-naphth-l-yl-piperazine-l-yl) prop-l-yl] -6-amino-2, 3-dihydro -l, 2-benzisothiazole-1, 1-dioxide with 2, 5-dimethoxytetrahydrofuran in glacial acetic acid at 100 ° C (1 h) in 86% yield.
  • Example 12 3, 3-Dimethyl-2- [3- (4-naphth-l-yl-piperazine-l-yl) prop-l-yl] -6-benzoylamido-2, 3-dihydro-l, 2-benzisothiazole-1,1-dioxide (mp: 127 ° C.).
  • Example 13 3, 3-Dimethyl-2- [3- (4-naphth-1-yl-piperazine-1-yl) prop-1-yl] -6-nitro-2, 3-dihydro-1, 2-benzisothiazole-1,1-dioxide (mp: 203 ° C.).
  • Example 14 3,3-Dimethyl-2- [2- (4- (2,3-dimethylphenyl) piperazin-1-yl) eth-l-yl] -2,3-dihydro-1,2 benzisothiazole-l, l-dioxide (mp: 291 ° C., hydrochloride).
  • Example 15 3, 3-Dimethyl-2- [2- (4-indan-4-yl-piperazine-1-yl) eth-1-yl] -2, 3-dihydro-1, 2-benzisothiazole- l, 1-dioxide (mp: 271 ° C, hydrochloride).
  • Example 16 3, 3-Dimethyl-2- [3- (4- (4-chloro-naphth-1-yl) piperazin-1-yl) prop-1-yl] -2, 3-dihydro-l, 2-benzisothiazole-l, l-dioxide (mp: 151 ° C.).
  • Example 17 3, 3-Dimethyl-2- [3- (4-pyrimidin-2-yl-piperazine-l-yl) prop-l-yl] -2, 3-dihydro-l, 2-benzisothiazole- l, 1-dioxide (mp: 263 ° C, hydrochloride).
  • Example 18 3,3-Dimethyl-2- [2- (4- (4-methoxyphenyl) piperazin-l-yl) eth-l-yl] -2, 3-dihydro-l, 2-benzoiso- thiazole-1,1-dioxide (mp: 207 ° C, hydrochloride).
  • Example 19 3,3-Dimethyl-2- [3- (4- (2-methoxyphenyl) piperazin-1-yl) -2-hydroxy-prop-l-yl] -2, 3-dihydro -l, 2-benzisothiazole-l, 1-dioxide (mp: 160 ° C).
  • Example 20 3,3-diethyl-2- [3- (4-naphth-l-yl-piperazine-l-yl) prop-l-yl] -2, 3-dihydro-l, 2-benzisothiazole- l, 1-dioxide (mp: 179 ° C).
  • Example 21 3,3-Dimethyl-2- [3- (4- (2,5-dimethylphenyl) piperazin-1-yl) prop-1-yl] -2,3-dihydro-1,2 benzisothiazole-1,1-dioxide (mp: 218 ° C., hydrochloride).
  • Example 22 3,3-Dimethyl-2- [2- (4- (2-cyano-phenyl) -piperazin-1-yl) -eth-1-yl] -2, 3-dihydro-1,2-benziso - thiazole-1,1-dioxide (mp: 228 ° C, hydrochloride).
  • One use according to the invention also relates to neuroprotection.
  • the use according to the invention can take place in the usual way orally or parenterally, intravenously or intramuscularly.
  • the dosage depends on the age, condition and weight of the patient and on the type of application.
  • the daily dose of active substance is between approximately 1 and 100 mg / kg body weight when administered orally and between 0.1 and 10 mg / kg body weight when administered parenterally.
  • the medicines can be used in common galenical forms of application in solid or liquid form, for example as tablets, film-coated tablets, capsules, powders, granules, dragees, suppositories, solutions, ointments, creams or sprays. These are manufactured in the usual way.
  • the active ingredients can be processed with the usual pharmaceutical auxiliaries such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, retardants, antioxidants and / or propellants (see H. Sucker et. Al: Pharmaceuticals Technology, Thieme-Verlag, Stuttgart, 1978).
  • the administration forms obtained in this way normally contain the active ingredient in an amount of 1 to 99% by weight.
  • central nervous disorders such as seasonal mood disorders and dysthymia.
  • anxiety such as generalized anxiety, panic attacks, sociophobia, obsessive-compulsive disorders and post-traumatic stress symptoms, memory disorders including dementia, amnesias and age-related memory loss as well as psychogenic eating disorders such as anorexia nervosa and bulimia nervosa.
  • A represents branched or unbranched (C ⁇ _ 10 ) alkylene or straight-chain or branched (C 2 - ⁇ o) alkylene which comprises at least one group Z which is selected from 0, S, NRs, cyclopropyl, C0 2 , CHOH , a double or a triple bond,
  • B represents 4-piperidine, 4-tetrahydro-l, 2, 3, 6 pyridine, 4-piperazine or the corresponding ring compounds enlarged by a methylene group, the linkage to A taking place via an N atom of B and
  • Ar for phenyl which is branched or unbranched by (C ⁇ _ 5 ) alkyl, O- (Ci_ 6 ) alkyl branched or unbranched, OH, F, Cl, Br, I, trifluoromethyl, NR 2 2 , C0 2 R 2 , cyano or substituted phenyl, tetralin, indane, more highly condensed aromatics such as naphthalene, which is optionally substituted by (C ⁇ ) alkyl or 0 (C ⁇ _- ⁇ ) alkyl, anthracene or 5- or 6-membered aromatic heterocycles having 1 to 2 heteroatoms, the are independently selected from O and N, which can also be fused with other aromatic radicals,
  • R ⁇ R 2 independently of one another are -CC 6 alkyl
  • R 3 , R 4 independently of one another for hydrogen, (C ⁇ _ 6 ) alkyl branched or unbranched, OH, O- (C ⁇ - 6 ) alkyl branched or unbranched, F, Cl, Br, I, trifluoromethyl, NR 5 R 6 , C0R 7 , nitro, cyano, pyrrole, for a phenylalkyl C 1 -C 4 radical, which in turn is aromatic on F, Cl, Br, I, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, trifluoromethyl, hydroxy, amino , Cyano or nitro may be substituted, R 5 , R 6 independently of one another for hydrogen, (C ⁇ _ 6 ) alkyl branched or unbranched, COPh, C0 2 tBu, CO- (C 1 -. 4 ) alkyl or together for a 5- or 6-membered ring which optionally contains a second N (for example piperazine),
  • R 7 represents hydrogen and (C ⁇ _ 6 ) alkyl branched or unbranched
  • R 8 represents hydrogen and C 1 -C 4 alkyl
  • R 9 for hydrogen, (C ⁇ _ 6 ) alkyl branched or unbranched, CO- (C 1 -) alkyl, C0 2 tBu, CO-aryl and a phenylalkyl -C-C 4 radical, which in turn on the aromatic through F, Cl, Br, I, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, trifluoromethyl, hydroxy, amino, cyano or nitro can be substituted,
  • One use according to the invention also relates to neuroprotection.
  • the preparation as a medicament is carried out with a compound of the formula I or its pharmacologically acceptable acid addition salt as an active ingredient, together with customary carrier and diluent.
  • a compound of the formula I or its pharmacologically acceptable acid addition salt as an active ingredient, together with customary carrier and diluent.
  • the use according to the invention can take place in the usual way orally or parenterally, intravenously or intramuscularly.
  • the dosage depends on the age, condition and weight of the patient and on the type of application.
  • the daily dose of active substance is between approximately 1 and 100 mg / kg body weight when administered orally and between 0.1 and 10 mg / kg body weight when administered parenterally.
  • the drugs can be used in common galenical forms of administration, solid or liquid, e.g. as tablets, film-coated tablets, capsules, powders, granules, dragees, suppositories, solutions, ointments, creams or sprays. These are manufactured in the usual way.
  • the active ingredients can be processed with the usual pharmaceutical auxiliaries such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, retardants, antioxidants and / or propellants (see H. Sucker et. Al: Pharmaceuticals Technology, Thieme-Verlag, Stuttgart, 1978).
  • the administration forms obtained in this way normally contain the active ingredient in an amount of 1 to 99% by weight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
EP99966990A 1999-01-11 1999-12-22 Verwendung von 2-substituierten 1,2-benzisothiazol-derivaten und von 3-substituierten tetrahydropyridopyrimidinon-derivaten zur prophylaxe und therapie der zerebralen ischämie Withdrawn EP1140099A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19900544 1999-01-11
DE19900544A DE19900544A1 (de) 1999-01-11 1999-01-11 Verwendung von Verbindungen der Formel I zur Prophylaxe und Therapie der zerebralen Ischämie
PCT/EP1999/010275 WO2000041697A1 (de) 1999-01-11 1999-12-22 Verwendung von 2-substituierten 1,2-benzisothiazol-derivaten und von 3-substituierten tetrahydropyridopyrimidinon-derivaten zur prophylaxe und therapie der zerebralen ischämie

Publications (1)

Publication Number Publication Date
EP1140099A1 true EP1140099A1 (de) 2001-10-10

Family

ID=7893835

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99966990A Withdrawn EP1140099A1 (de) 1999-01-11 1999-12-22 Verwendung von 2-substituierten 1,2-benzisothiazol-derivaten und von 3-substituierten tetrahydropyridopyrimidinon-derivaten zur prophylaxe und therapie der zerebralen ischämie

Country Status (19)

Country Link
EP (1) EP1140099A1 (hu)
JP (1) JP2002534467A (hu)
KR (1) KR20010101440A (hu)
CN (1) CN1333685A (hu)
AR (1) AR029741A1 (hu)
AU (1) AU2285100A (hu)
BG (1) BG105688A (hu)
BR (1) BR9916888A (hu)
CA (1) CA2359390A1 (hu)
DE (1) DE19900544A1 (hu)
HU (1) HUP0200520A3 (hu)
IL (1) IL144145A0 (hu)
MX (1) MXPA01006966A (hu)
NO (1) NO20013408L (hu)
PL (1) PL348916A1 (hu)
SK (1) SK9682001A3 (hu)
TR (1) TR200102009T2 (hu)
WO (1) WO2000041697A1 (hu)
ZA (1) ZA200105473B (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
JP4794446B2 (ja) * 2003-09-23 2011-10-19 メルク・シャープ・エンド・ドーム・コーポレイション イソキノリン系カリウムチャンネル阻害薬
US8097610B2 (en) * 2005-08-26 2012-01-17 Shionogi & Co., Ltd. Derivative having PPAR agonistic activity
WO2009038752A2 (en) * 2007-09-20 2009-03-26 Cortex Pharmaceuticals, Inc. 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses
MA41168A (fr) 2014-12-17 2017-10-24 Acraf Nouveaux composés antibactériens
CN108484594B (zh) * 2018-02-09 2020-08-04 福建医科大学 一种烷氧基取代四氢吡啶并嘧啶类化合物或其可用盐及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3620643A1 (de) * 1985-06-22 1987-01-22 Sandoz Ag Thiazole, ihre herstellung und verwendung
DE3831888A1 (de) * 1988-09-20 1990-03-29 Troponwerke Gmbh & Co Kg Arzneimittel zur behandlung von apoplexia cerebri
JP3036789B2 (ja) * 1990-06-22 2000-04-24 三井化学株式会社 新規な複素環式化合物及び医薬組成物
DE19746612A1 (de) * 1997-10-22 1999-04-29 Basf Ag 2-Substituierte 1,2-Benzisothiazol-Derivate, ihre Herstellung und Verwendung
DE19747063A1 (de) * 1997-10-24 1999-04-29 Basf Ag 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0041697A1 *

Also Published As

Publication number Publication date
CA2359390A1 (en) 2000-07-20
BR9916888A (pt) 2001-11-20
HUP0200520A3 (en) 2003-04-28
SK9682001A3 (en) 2002-03-05
JP2002534467A (ja) 2002-10-15
KR20010101440A (ko) 2001-11-14
BG105688A (en) 2002-02-28
MXPA01006966A (es) 2002-04-10
AR029741A1 (es) 2003-07-16
WO2000041697A1 (de) 2000-07-20
CN1333685A (zh) 2002-01-30
HUP0200520A2 (hu) 2002-07-29
ZA200105473B (en) 2002-10-03
IL144145A0 (en) 2002-05-23
NO20013408D0 (no) 2001-07-10
PL348916A1 (en) 2002-06-17
DE19900544A1 (de) 2000-07-13
TR200102009T2 (tr) 2002-01-21
NO20013408L (no) 2001-08-21
AU2285100A (en) 2000-08-01

Similar Documents

Publication Publication Date Title
DE69232665T2 (de) Neue 4-arylpiperazine und 4-arylpiperidine
DE60315516T2 (de) Pyridazinon-derivate als cdk2-hemmer
DE3248160C2 (de) 2-[4-[(4,4-Dialkyl-2,6-piperidindion-1-yl)-butyl]-1-piperazinyl]pyrimidine, Verfahren zu ihrer Herstellung und pharmazeutische Mittel, die diese Verbindungen enthalten
EP1025100B1 (de) 3-substituierte tetrahydropyridopyrimidinon-derivate, ihre herstellung und verwendung
DE2415082A1 (de) Disubstituierte piperazine, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE60004671T2 (de) Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung
EP0101574A1 (de) 2-Substituierte 1-Aminoalkyl-1,2,3,4-tetrahydro-beta-carboline, ihre Herstellung und Verwendung als Arzneimittel
EP1140096A1 (de) Verwendung von pyrimidinderivaten zur prophylaxe und therapie der zerebralen ischämie
AT391698B (de) Verfahren zur herstellung neuer zyklischer imid- derivate von 2-(4-butylpiperazin-1-yl)-pyridinen
DE3615180C2 (de) Disubstituierte 1,4-Piperazinylderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Mittel
WO2000041697A1 (de) Verwendung von 2-substituierten 1,2-benzisothiazol-derivaten und von 3-substituierten tetrahydropyridopyrimidinon-derivaten zur prophylaxe und therapie der zerebralen ischämie
DE4325900A1 (de) Trisubstituierte Pyrimido [5,4-d] pyrimidine zur Modulation der Multidrugresistenz, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1034170A1 (en) 2-substituted 1,2-benzisothiazole derivatives and their use as serotonin antagonists (5-ht1a, 5-ht1b and 5-ht1d)
EP2029580B1 (de) Neue indol-pyrrol-derivate zur behandlung proliferativer und inflammatorischer krankheiten
EP0139993A2 (de) Chinazolinderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE3404193C2 (hu)
EP1023296A1 (de) 3-SUBSTITUIERTE PYRIDO 3',4':4,5] THIENO 2,3-d] PYRIMIDIN-DERIVATE, IHRE HERSTELLUNG UND VERWENDUNG
EP0580644B1 (de) 1,3,4-trisubstituierte piperidin-derivate, ihre herstellung und verwendung
DE3529872A1 (de) Neue tetraoxoverbindungen
EP0731801B1 (de) Substituierte aminoalkylaminopyridine
WO2011151701A1 (en) 6 - methyl - 4 - phenyl - 5 - ( phenyl or cycloalkyl) carbamoyl - 1,2,3, 4 - tetrahydropyrimidin- 2 - one derivatives as antitubercular agents
CZ20001436A3 (cs) Disubstituované deriváty 1,2-benzisotiazolu a jejich použití
MXPA00002601A (en) 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use
MXPA00003136A (en) 2-substituted 1,2-benzisothiazole derivatives and their use as serotonin antagonists (5-ht1a, 5-ht1b and 5-ht1d)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010619

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO PAYMENT 20010619;SI PAYMENT 20010619

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030217